Outlook Therapeutics Inc.

NASDAQ: OTLK · Real-Time Price · USD
2.40
-0.03 (-1.23%)
At close: Aug 15, 2025, 12:45 PM

Outlook Therapeutics Income Statement

Financials in USD. Fiscal year is October - September.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Sep 30, 2024 Sep 30, 2023 Sep 30, 2022 Sep 30, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
113.86K 44.19K 204.69K 262.14K
Gross Profit
-113.86K -44.19K -204.69K -262.14K
Operating Income
-71.7M -53.13M -63.07M -51.73M
Interest Income
906.15K n/a n/a n/a
Pretax Income
-75.36M -58.98M -66.05M -53.16M
Net Income
-75.37M -58.98M -66.05M -53.16M
Selling & General & Admin
29.94M 26.67M 20.74M 12.77M
Research & Development
41.76M 26.45M 42.33M 38.96M
Other Expenses
n/a n/a -205K n/a
Operating Expenses
71.7M 53.13M 62.87M 51.73M
Interest Expense
3.16M 1.56M 1.49M 936.13K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
71.7M 53.13M 63.07M 51.73M
Income Tax Expense
2.8K 2.8K 2.8K 2K
Shares Outstanding (Basic)
18.55M 12.51M 10.6M 7.63M
Shares Outstanding (Diluted)
18.55M 12.51M 10.6M 7.63M
EPS (Basic)
-4.06 -4.72 -6.23 -6.96
EPS (Diluted)
-4.06 -4.72 -6.23 -6.96
EBITDA
-72.09M -57.38M -64.36M -51.51M
EBIT
-72.21M -57.42M -64.56M -51.73M
Depreciation & Amortization
113.86K 44.19K 204.69K 262.14K